Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fruquintinib + mFOLFOX6/FOLFIRI in First-line Metastatic Colorectal Cancer
NCT05004441Phase 2Completed
- Start
- Jul 2021
- Primary completion
- May 2023
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of fruquintinib in colorectal cancer (CRC). Primary endpoint: Objective Response Rate at 36 months. Started Jul 2021; status: completed.
02
Drugs
fruquintinib
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT05004441.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05004441.